UBS Group’s Biofrontera BFRIW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13 Hold
343
﹤0.01% 10315
2025
Q4
$31 Buy
+343
New +$32 ﹤0.01% 10314
2025
Q2
Sell
-891
Closed -$54 10258
2025
Q1
$54 Sell
891
-1,628
-65% -$122 ﹤0.01% 10003
2024
Q4
$154 Sell
2,519
-3,805
-60% -$258 ﹤0.01% 9597
2024
Q3
$145 Buy
6,324
+6,314
+63,140% +$233 ﹤0.01% 9116
2024
Q2
$0 Sell
10
-2,594
-100% -$133 ﹤0.01% 9524
2024
Q1
$177 Buy
2,604
+2,394
+1,140% +$70 ﹤0.01% 8756
2023
Q4
$2 Buy
210
+141
+204% +$4 ﹤0.01% 9187
2023
Q3
$2 Buy
+69
New +$6 ﹤0.01% 9342
2023
Q1
Sell
-10
Closed -$2 9613
2022
Q4
$2 Sell
10
-4,273
-100% -$1.73K ﹤0.01% 10644
2022
Q3
$2K Buy
4,283
+430
+11% +$268 ﹤0.01% 9694
2022
Q2
$3K Buy
+3,853
New +$4.25K ﹤0.01% 9284
2022
Q1
Sell
-2,750
Closed -$10K 10257
2021
Q4
$10K Buy
+2,750
New +$5.93K ﹤0.01% 8758

Other funds holding BFRIW

UBS Group's BFRIW Position: Q1 2026 in Review

UBS Group held its Biofrontera (BFRIW) position steady in Q1 2026 at 343 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #10315.

UBS Group first reported a position in BFRIW in Q4 2021 and has held it in 13 quarters since. The position peaked at $10K in Q4 2021. 6 funds tracked by Wall St. Rank hold BFRIW as of Q1 2026.

  • UBS Group held 343 shares of Biofrontera worth $13 as of Q1 2026.
  • UBS Group left its Biofrontera share count unchanged in Q1 2026.
  • Biofrontera made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10315 holding.
  • UBS Group first reported a position in Biofrontera in Q4 2021 and has held it in 13 quarters since.
  • UBS Group's Biofrontera position peaked at $10K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Biofrontera as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.